Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program.
The clinical success of the application of tumor necrosis factor-alpha (TNFalpha) in isolated limb perfusions in patients with advanced sarcomas, melanomas and other tumors has renewed the interest in this agent as an anticancer drug. At the Rotterdam Cancer Center, we have developed an interactive preclinical-clinical TNFalpha program that explores new methods to use TNFalpha in various settings. Regional organ perfusion models were developed and the effectivity of targeting of TNFalpha to the tumor by means of systemic administration of liposomes are tested. Furthermore various drugs and mechanisms that may enhance the activity of TNFalpha are under investigation. A summary of this comprehensive program is presented here.
Manusama
E R
ER
Department of Surgical Oncology, University Hospital Rotterdam, Daniel den Hoed Cancer Center, The Netherlands.
Nooijen
P T
PT
Ten Hagen
T L
TL
Van Der Veen
A H
AH
De Vries
M W
MW
De Wilt
J H
JH
Van Ijken
M G
MG
Marquet
R L
RL
Eggermont
A M
AM
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion; D004337:Drug Carriers; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use; D008081:Liposomes; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D009569:Nitric Oxide / Q000502:physiology; D010477:Perfusion; D051381:Rats; D011994:Recombinant Proteins; D013552:Swine; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000627:therapeutic use
D004337:Drug Carriers; D008081:Liposomes; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D007371:Interferon-gamma; D008558:Melphalan